What's Happening?
MaaT Pharma, a clinical-stage biotechnology company, has announced its 2025 annual results and provided updates on its business activities. The company reported a 38% increase in revenues from its Early Access Program, totaling €4.4 million. MaaT Pharma is
advancing its microbiome ecosystem therapies, with a focus on enhancing cancer patient survival through immune modulation. The company submitted a Marketing Authorization Application for MaaT013 to the European Medicines Agency, with feedback expected in mid-2026. MaaT033, another drug candidate, is in Phase 2b trials, with results anticipated in 2028. MaaT Pharma also secured a €37.5 million financing agreement with the European Investment Bank to support its pipeline.
Why It's Important?
MaaT Pharma's progress in microbiome-driven therapies represents a significant development in cancer treatment, offering new therapeutic options for patients with high unmet needs. The company's focus on immune modulation through microbiome therapies could lead to improved survival rates for cancer patients. The submission of MaaT013 for EMA review marks a potential milestone in oncology, with the drug candidate being developed for rare diseases. The financial agreements and increased revenues reflect growing adoption and support for MaaT Pharma's innovative approach, positioning the company as a leader in microbiome-driven therapies.
What's Next?
MaaT Pharma is preparing for the EMA review of MaaT013, which could lead to first-in-class approval in oncology. The company is also evaluating regulatory pathways for potential FDA submission in the U.S., with ongoing interactions to refine clinical study designs. MaaT Pharma plans to expand its U.S. footprint through its Early Access Program, with patient requests from leading hospitals. The company is focusing on GMP batch production and regulatory readiness for MaaT034, targeting a First-in-Human trial start in 2027, subject to funding.
